Drugs / CD7-specific CAR-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06720324 | Dec 2024 → Dec 2027 expected | hematopoietic and lymphoid cell neoplasm | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD7-specific CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06720324 ↗ |
| Action | Deplete | “Since endogenous CD7 in T cells causes CD7-targeting CAR-T cells to kill each other” NCT06720324 ↗ |
| Modality | Cell therapy | “CD7-specific CAR-T cells” NCT06720324 ↗ |
| Target | CD7 | “The CD7-targeting fragment was cloned into a second-generation CAR structural backbone with 4-1BB and CD3E.” NCT06720324 ↗ |